SeedToB Capital

Co-founders Shantanu Nigam and Ritesh Sharma lead investment decisions as Managing Partners. Both are former operators — Nigam was CEO and Sharma was COO of Jvion, the clinical AI platform they built and sold — giving them direct tactical authority over the firm’s healthcare-focused thesis.

Deal flow runs largely through the founders’ decades-old relationships with hospital systems, payers, and digital health investors cultivated during their Jvion years. Portfolio founder Eller Kelliher, based in Nashville and previously Managing Director of Jumpstart Foundry, provides an additional sourcing channel into one of the densest healthcare innovation hubs in the US.

SeedToB operates as an asset manager, not a family office. It is a private equity firm deploying pooled capital into early-stage healthcare companies, distinct from managing a single family’s wealth.

The firm highlights only direct investments in Seed and Series A healthcare technology companies. There is no public indication it commits capital to external funds as a limited partner.

SeedToB targets Seed and Series A rounds, with initial checks of $500,000 to $1.5 million. The firm explicitly structures its support to help startups reach Series B, and states an intention to provide follow-on capital through the early stage.

SeedToB invests only in healthcare technology companies. It does not pursue non-healthcare verticals, and within healthcare it targets AI-enabled software and diagnostics — there is no evidence it invests in services, devices, or therapeutics businesses without a central AI or advanced technology component.

Nigam and Sharma took Jvion from founding through a 2019 private equity acquisition. That pattern — building a clinically validated AI platform, scaling it to industry leadership as measured by Blackbook and KLAS (2018), and exiting — is the operational model they now replicate to help portfolio founders chart the most efficient path to Series B.